Quick Answer
Trevi Therapeutics, Inc. reported Diluted EPS of $0.32 per share (loss) for fiscal year 2025.
Trevi Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.32 | +31.9% |
| 2024 | -$0.47 | -62.1% |
| 2023 | -$0.29 | +35.6% |
| 2022 | -$0.45 | +69.8% |
| 2021 | -$1.49 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.08 | +38.5% | +11.1% |
| June 30, 2025 | -$0.09 | +25.0% | +0.0% |
| March 31, 2025 | -$0.09 | +18.2% | +30.8% |
| September 30, 2024 | -$0.13 | -62.5% | -8.3% |
| June 30, 2024 | -$0.12 | -71.4% | -9.1% |
| March 31, 2024 | -$0.11 | -83.3% | -37.5% |
| September 30, 2023 | -$0.08 | +33.3% | -14.3% |
| June 30, 2023 | -$0.07 | +50.0% | -16.7% |
- Trevi Therapeutics, Inc. showed an increase of +31.9% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Trevi Therapeutics, Inc.’s diluted eps has grown by 78.5% (from $1.49 per share (loss) to $0.32 per share (loss)).
- The most recent figure is from Trevi Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: